Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q, Duan W, Reeves SA, Cattaneo E, Krainc D.

J Neurosci. 2011 Jun 29;31(26):9544-53. doi: 10.1523/JNEUROSCI.1291-11.2011.

2.

Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease.

Johri A, Starkov AA, Chandra A, Hennessey T, Sharma A, Orobello S, Squitieri F, Yang L, Beal MF.

Neurodegener Dis. 2011;8(6):496-503. doi: 10.1159/000327910. Epub 2011 Jul 15.

3.

Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice.

Massa PT, Wu C, Fecenko-Tacka K.

J Neurosci Res. 2004 Jul 1;77(1):15-25.

PMID:
15197735
4.

Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.

Jin J, Peng Q, Hou Z, Jiang M, Wang X, Langseth AJ, Tao M, Barker PB, Mori S, Bergles DE, Ross CA, Detloff PJ, Zhang J, Duan W.

Hum Mol Genet. 2015 May 1;24(9):2508-27. doi: 10.1093/hmg/ddv016. Epub 2015 Jan 21.

5.

A transgenic mouse model for inducible and reversible dysmyelination.

Mathis C, Hindelang C, LeMeur M, Borrelli E.

J Neurosci. 2000 Oct 15;20(20):7698-705.

6.

Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.

Martin E, Betuing S, Pagès C, Cambon K, Auregan G, Deglon N, Roze E, Caboche J.

Hum Mol Genet. 2011 Jun 15;20(12):2422-34. doi: 10.1093/hmg/ddr148. Epub 2011 Apr 14.

7.

Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease.

Xiang Z, Krainc D.

J Huntingtons Dis. 2013;2(1):101-5. doi: 10.3233/JHD-130046.

PMID:
25063433
8.

Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease.

Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, Olson JM, Sipione S, Tartari M, Cattaneo E.

J Neurosci. 2005 Oct 26;25(43):9932-9.

9.

Study of cholesterol metabolism in Huntington's disease.

Leoni V, Caccia C.

Biochem Biophys Res Commun. 2014 Apr 11;446(3):697-701. doi: 10.1016/j.bbrc.2014.01.188. Epub 2014 Feb 10. Review.

PMID:
24525128
10.

Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β.

Jana M, Mondal S, Gonzalez FJ, Pahan K.

J Biol Chem. 2012 Oct 5;287(41):34134-48. doi: 10.1074/jbc.M112.398552. Epub 2012 Aug 9.

11.

Myelination deficit in a phencyclidine-induced neurodevelopmental model of schizophrenia.

Zhang R, He J, Zhu S, Zhang H, Wang H, Adilijiang A, Kong L, Wang J, Kong J, Tan Q, Li XM.

Brain Res. 2012 Aug 21;1469:136-43. doi: 10.1016/j.brainres.2012.06.003. Epub 2012 Jun 29.

PMID:
22750584
12.

Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.

Chaturvedi RK, Hennessey T, Johri A, Tiwari SK, Mishra D, Agarwal S, Kim YS, Beal MF.

Hum Mol Genet. 2012 Aug 1;21(15):3474-88. doi: 10.1093/hmg/dds178. Epub 2012 May 15.

13.

Cellular expression of an HMGCR promoter-CAT fusion gene in transgenic mouse brain: evidence for a developmental regulation in oligodendrocytes.

Duhamel-Clerin E, Villarroya H, Mehtali M, Lapie P, Besnard F, Gumpel M, Lachapelle F.

Glia. 1994 May;11(1):35-46.

PMID:
8070893
14.

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Chan EY, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR, Cha JH, Aronin N, Hayden MR, Olson JM.

Hum Mol Genet. 2002 Aug 15;11(17):1939-51.

15.

On the occurrence of hypomyelination in a transgenic mouse model: a consequence of the myelin basic protein promoter?

Gaupp S, Arezzo J, Dutta DJ, John GR, Raine CS.

J Neuropathol Exp Neurol. 2011 Dec;70(12):1138-50. doi: 10.1097/NEN.0b013e31823b188b.

16.

Oligodendroglial expression of TrkB independently regulates myelination and progenitor cell proliferation.

Wong AW, Xiao J, Kemper D, Kilpatrick TJ, Murray SS.

J Neurosci. 2013 Mar 13;33(11):4947-57. doi: 10.1523/JNEUROSCI.3990-12.2013.

17.

Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.

Mattan NS, Ghiani CA, Lloyd M, Matalon R, Bok D, Casaccia P, de Vellis J.

Neurobiol Dis. 2010 Nov;40(2):432-43. doi: 10.1016/j.nbd.2010.07.003. Epub 2010 Jul 14.

19.

Role of transmembrane semaphorin Sema6A in oligodendrocyte differentiation and myelination.

Bernard F, Moreau-Fauvarque C, Heitz-Marchaland C, Zagar Y, Dumas L, Fouquet S, Lee X, Shao Z, Mi S, Chédotal A.

Glia. 2012 Oct;60(10):1590-604. doi: 10.1002/glia.22378. Epub 2012 Jul 9.

PMID:
22777942
20.

Recovery of myelin after induction of oligodendrocyte cell death in postnatal brain.

Jalabi W, Boehm N, Grucker D, Ghandour MS.

J Neurosci. 2005 Mar 16;25(11):2885-94.

Items per page

Supplemental Content

Write to the Help Desk